Type 1 diabetes (insulin-dependent diabetes mellitus, IDDM) is characterized by low or absent levels of endogenously produced insulin, as a consequence of the autoimmune destruction of pancreatic (3-cells. The US incidence of IDDM in children up to 14-year-old is estimated in the range of 12 to 20 per 100,000, with an increasing incidence worldwide. At present, there is no an effective therapy to prevent or cure the disease in humans. We have genetically engineered a dimeric MHC class II (I-Ed)/Fc, namely DEF, molecule containing a CD4 T cell epitope (HAl10-120) of hemagglutinin (HA) of influenza A/PR/8/34 virus. DEF molecule exerts different immunomodulatory effects on the specific T cells depending on the dose: low doses polarize resting and activated T cells toward Th2 phenotype, and high doses induce central tolerance and peripheral energy. We propose to evaluate the protective and curative capacity of DEF in an animal model for autoimmune diabetes. The animal model consists in double transgenic (dTg) mice expressing HA of influenza virus in the pancreatic (3-cells, and at the same time the specific T cell receptor (TCR- HA) for the immunodominant epitope HA1 10-120. The dTg mice develop insulitis, hyperglycemia, and hypoinsulinemia early in life. We will investigate the immunomdulatory mechanisms responsible for the prophylactic and curative capacity of low and high doses of DEF in dTg mice. Human DEF-like molecules may represent a new approach for the prevention and treatment of type 1 diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
James A. Shannon Director's Award (R55)
Project #
1R55DK055744-01A1
Application #
6128241
Study Section
Immunological Sciences Study Section (IMS)
Program Officer
Akolkar, Beena
Project Start
2000-09-30
Project End
2002-08-31
Budget Start
2000-09-30
Budget End
2002-08-31
Support Year
1
Fiscal Year
2000
Total Cost
$100,000
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Casares, Sofia; Hurtado, Alicia; McEvoy, Robert C et al. (2002) Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 3:383-91
Casares, S; Bona, C A; Brumeanu, T D (2001) Enzymatically mediated engineering of multivalent MHC class II-peptide chimeras. Protein Eng 14:195-200
Casares, S; Stan, A C; Bona, C A et al. (2001) Antigen-specific downregulation of T cells by doxorubicin delivered through a recombinant MHC II--peptide chimera. Nat Biotechnol 19:142-7
Casares, S; Bona, C A; Brumeanu, T D (2001) Modulation of CD4 T cell function by soluble MHC II-peptide chimeras. Int Rev Immunol 20:547-73